Published in Thromb Haemost on February 02, 2010
Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med (2010) 3.32
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ (2011) 2.68
Personalised medicine: not just in our genes. BMJ (2012) 1.51
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J (2013) 0.96
Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med (2011) 0.93
Anti-platelet therapy: ADP receptor antagonists. Br J Clin Pharmacol (2011) 0.92
Determinants to optimize response to clopidogrel in acute coronary syndrome. Pharmgenomics Pers Med (2010) 0.87
Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics. PLoS Curr (2010) 0.84
Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population. Clin Transl Sci (2016) 0.80
A high ratio of ADP-TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone. Clin Res Cardiol (2014) 0.80
Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations. Br J Clin Pharmacol (2011) 0.79
Inflammatory and antioxidant pattern unbalance in "clopidogrel-resistant" patients during acute coronary syndrome. Mediators Inflamm (2015) 0.78
Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommended. Hawaii J Med Public Health (2015) 0.78
Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese population. PLoS One (2012) 0.78
Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1. Ther Adv Drug Saf (2011) 0.76
Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention. Ann Med (2011) 0.76
Genetic determinations of variable responsiveness to clopidogrel and implications for neurointerventional procedures. Interv Neurol (2012) 0.76
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. Ann Med (2014) 0.75
The Ratio of ADP- to TRAP-Induced Platelet Aggregation Quantifies P2Y12-Dependent Platelet Inhibition Independently of the Platelet Count. PLoS One (2016) 0.75
Early surgery after coronary revascularization: a fine line between bleeding and thrombosis. Transl Med UniSa (2014) 0.75
Effect of Oral Anti-platelet Regimens on Platelet Aggregation using Chronolog Light Transmittance Aggregometry in Coronary Heart Disease Patients: An Observational Study. J Clin Diagn Res (2013) 0.75
Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention. Exp Ther Med (2016) 0.75
The P2Y(12) receptor as a target of antithrombotic drugs. Purinergic Signal (2011) 0.75
Circulating primers enhance platelet function and induce resistance to antiplatelet therapy. J Thromb Haemost (2015) 0.75
Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes. Patient Relat Outcome Meas (2010) 0.75
Characterization of surface antigens of reticulated immature platelets. J Thromb Thrombolysis (2017) 0.75
Dynamic changes and associated factors of clopidogrel resistance in patients after cerebral infarction. J Neurol (2013) 0.75
Biomarkers in acute coronary artery disease. Wien Med Wochenschr (2012) 0.75
Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut (2012) 12.62
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Adherence to Mediterranean diet and health status: meta-analysis. BMJ (2008) 4.16
Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr (2010) 3.99
Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol (2007) 3.20
Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol (2013) 2.56
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol (2010) 2.55
Long-term prognostic role of uric acid in patients with ST-elevation myocardial infarction and renal dysfunction. J Cardiovasc Med (Hagerstown) (2015) 2.30
Seasonal blood pressure changes: an independent relationship with temperature and daylight hours. Hypertension (2013) 2.30
Carotid artery stenting: first consensus document of the ICCS-SPREAD Joint Committee. Stroke (2006) 2.21
Physical activity during leisure time and primary prevention of coronary heart disease: an updated meta-analysis of cohort studies. Eur J Cardiovasc Prev Rehabil (2008) 2.14
Mechanical ventilation in the early phase of ST elevation myocardial infarction treated with mechanical revascularization. Cardiol J (2013) 2.06
Weather-related changes in 24-hour blood pressure profile: effects of age and implications for hypertension management. Hypertension (2005) 2.05
Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol (2011) 2.05
Strong-ion gap approach in patients with cardiogenic shock following ST-elevation myocardial infarction. Acute Card Care (2013) 2.03
Abnormal troponin level as short-term predictor of poor outcome in acute atrial fibrillation. Am J Emerg Med (2013) 2.02
Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents. Am J Cardiol (2013) 2.00
Cryptogenic myocardial infarction in young patients: which is the optimal diagnostic and therapeutic management? Arch Iran Med (2013) 1.99
Five-year echocardiographic results of combined undersized mitral ring annuloplasty and coronary artery bypass grafting for chronic ischaemic mitral regurgitation. Eur Heart J (2007) 1.93
EXCAVATOR: detecting copy number variants from whole-exome sequencing data. Genome Biol (2013) 1.90
Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. Am J Hum Genet (2009) 1.87
Analysis of minK and eNOS genes as candidate loci for predisposition to non-valvular atrial fibrillation. Eur Heart J (2006) 1.82
Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis. Am J Med (2007) 1.76
Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thromb Haemost (2009) 1.75
Prognostic value of 6-minute walk corridor test in patients with mild to moderate heart failure: comparison with other methods of functional evaluation. Eur J Heart Fail (2003) 1.70
Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: its prognostic role and relation with inflammatory markers: a single center experience. Int J Cardiol (2008) 1.66
Left ventricular reverse remodeling after undersized mitral ring annuloplasty in patients with ischemic regurgitation. Ann Thorac Surg (2008) 1.65
Assessment of cardiac output in children: a comparison between the pressure recording analytical method and Doppler echocardiography. Pediatr Crit Care Med (2008) 1.64
Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol (2008) 1.64
Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. Am J Med (2003) 1.60
Phenotypic variability of cardiovascular manifestations in Marfan Syndrome. Possible role of hyperhomocysteinemia and C677T MTHFR gene polymorphism. Eur Heart J (2003) 1.59
Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol (2009) 1.58
Evaluation of traditional and emerging cardiovascular risk factors in patients with non-arteritic anterior ischemic optic neuropathy: a case-control study. Graefes Arch Clin Exp Ophthalmol (2008) 1.57
Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol (2009) 1.57
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J Am Coll Cardiol (2003) 1.54
Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study. Circulation (2006) 1.54
An unusual case of cardiac tamponade. J Cardiovasc Med (Hagerstown) (2006) 1.53
[Non-alcoholic fatty liver disease: a new challenge for cardiologists]. G Ital Cardiol (Rome) (2010) 1.52
High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. Am J Med (2002) 1.50
Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy. Thromb Haemost (2007) 1.50
Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function. Thromb Haemost (2008) 1.49
Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine. Stroke (2005) 1.49
Management of acute myocardial infarction in the real world: a summary report from The Ami-Florence Italian Registry. Intern Emerg Med (2008) 1.48
Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am J Clin Pathol (2009) 1.48
High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study. JACC Cardiovasc Interv (2013) 1.47
Role of hemodynamic shear stress in cardiovascular disease. Atherosclerosis (2010) 1.47
Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics (2007) 1.43